This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:othertreatments:chemotherapy [11.13.2011] – [Rituximab] paulalbert | home:othertreatments:chemotherapy [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 19: | Line 19: | ||
There are variety of kinds of chemotherapy, | There are variety of kinds of chemotherapy, | ||
- | When the body is immunosuppressed, | + | When the body is immunosuppressed, |
- | The additional immunosuppression caused by chemotherapy can cause symptoms over the long-term such as "chemo brain." | + | The additional immunosuppression caused by chemotherapy can cause symptoms over the long-term such as "chemo brain." |
+ | ==== Chemo brain ==== | ||
+ | Brain fog (also known as "chemo brain" | ||
- | ===== Methotrexate ===== | ||
- | Methotrexate (MTX) is an antibiotic, which interferes with bacteria' | ||
- | < | ||
- | The interesting thing is that Folic Acid supplements are often given to ease the "side effects" | ||
- | //**Trevor Marshall, PhD**// </ | ||
- | ==== Discontinuing methotrexate ==== | ||
- | The antibiotic action of MTX is likely to increase the immunopathology associated with olmesartan | + | ===== Methotrexate ===== |
+ | |||
+ | < | ||
+ | |||
+ | Methotrexate | ||
- | It is not harmful to the body to discontinue MTX abruptly. This is in contrast to Prednisone, where abruptly stopping can cause a number of serious problems. Some doctors think there is a risk of rebound inflammation from stopping methotrexate abruptly. Taking a few weeks to wean from MTX, while probably not necessary, is the cautious approach to avoid the symptoms of rebound inflammation. | ||
===== Rituximab ===== | ===== Rituximab ===== | ||
- | In 2011, a Norwegian study published in //PLoS One// studied the effect of Rituximab – a monoclonal antibody otherwise used in cancers and anti-rejection treatment for organ transplants – on patients with chronic fatigue syndrome. In the 25-week study period, fatigue improved significantly in 10 out of 15 patients versus 2 out of 15 controls.(({{pubmed> | + | In 2011, a Norwegian study published in //PLoS One// studied the effect of Rituximab – a monoclonal antibody otherwise used in cancers and anti-rejection treatment for organ transplants – on patients with chronic fatigue syndrome. In the 25-week study period, fatigue improved significantly in 10 out of 15 patients versus 2 out of 15 controls.(({{pmid> |
===== Patient interviews | ===== Patient interviews | ||
Line 58: | Line 57: | ||
sarcoidosis, | sarcoidosis, | ||
- | Read the [[http:// | + | Read the [[https:// |
< | < | ||
Line 90: | Line 89: | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
- | TECHEDIT | + | |
* Legacy content | * Legacy content | ||
- | * http:// | + | * https:// |
- | * http:// | + | * https:// |
- | * http:// | + | * https:// |
* | * | ||
Line 109: | Line 109: | ||
3. SavageL.High-intensitychemotherapydoesnotimprovesurvivalinsmallcelllung cancer. J Natl Cancer Inst. 2008; | 3. SavageL.High-intensitychemotherapydoesnotimprovesurvivalinsmallcelllung cancer. J Natl Cancer Inst. 2008; | ||
- | //**H.H. Weng**// | + | //**H.H. Weng**// |
Some more interesting stuff here: | Some more interesting stuff here: | ||
- | http:// | + | https:// |
In cancer research, system behavior has been monitored during cancer progression, | In cancer research, system behavior has been monitored during cancer progression, | ||
Line 122: | Line 122: | ||
- | < | + | < |
- | ===== References ===== | + | ===== References =====</ |